Literature DB >> 28744011

NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib.

S Sopper1,2, S Mustjoki3,4, B T Gjertsen5, F Giles6, A Hochhaus7, J J W M Janssen8, K Porkka3, D Wolf1,2,9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28744011     DOI： 10.1038/leu.2017.235

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Detection of the BCR-ABL fusion gene in natural killer cells in patients with chronic myelogenous leukemia.

Authors:  C K Min; I H Yang; D W Kim; J W Lee; C W Han; W S Min; C C Kim
Journal:  Acta Haematol       Date:  2000       Impact factor: 2.195

2.  Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia.

Authors:  E K Cho; D S Heo; J G Seol; E J Seo; H S Chi; E S Kim; Y Y Lee; B K Kim; N K Kim
Journal:  Br J Haematol       Date:  2000-10       Impact factor: 6.998

3.  Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Authors:  C Schütz; S Inselmann; S Saussele; C T Dietz; M C Mu Ller; E Eigendorff; C A Brendel; S K Metzelder; T H Bru Mmendorf; C Waller; J Dengler; M E Goebeler; R Herbst; G Freunek; S Hanzel; T Illmer; Y Wang; T Lange; F Finkernagel; R Hehlmann; M Huber; A Neubauer; A Hochhaus; J Guilhot; F Xavier Mahon; M Pfirrmann; A Burchert
Journal:  Leukemia       Date:  2017-01-11       Impact factor: 11.528

4.  Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

Authors:  Elias Jabbour; Hagop M Kantarjian; Giuseppe Saglio; Juan Luis Steegmann; Neil P Shah; Concepción Boqué; Charles Chuah; Carolina Pavlovsky; Jirí Mayer; Jorge Cortes; Michele Baccarani; Dong-Wook Kim; M Brigid Bradley-Garelik; Hesham Mohamed; Mark Wildgust; Andreas Hochhaus
Journal:  Blood       Date:  2013-12-05       Impact factor: 22.113

5.  JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms.

Authors:  Kathrin Schönberg; Janna Rudolph; Maria Vonnahme; Sowmya Parampalli Yajnanarayana; Isabelle Cornez; Maryam Hejazi; Angela R Manser; Markus Uhrberg; Walter Verbeek; Steffen Koschmieder; Tim H Brümmendorf; Peter Brossart; Annkristin Heine; Dominik Wolf
Journal:  Cancer Res       Date:  2015-04-01       Impact factor: 12.701

6.  The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.

Authors:  Hikaru Nakajima; Robert Zhao; Troy C Lund; Jeanne Ward; Michelle Dolan; Betsy Hirsch; Jeffrey S Miller
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

7.  Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization.

Authors:  N Takahashi; I Miura; K Saitoh; A B Miura
Journal:  Blood       Date:  1998-12-15       Impact factor: 22.113

8.  Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

Authors:  A Hochhaus; G Rosti; N C P Cross; J L Steegmann; P le Coutre; G Ossenkoppele; L Petrov; T Masszi; A Hellmann; L Griskevicius; W Wiktor-Jedrzejczak; D Rea; D Coriu; T H Brümmendorf; K Porkka; G Saglio; G Gastl; M C Müller; P Schuld; P Di Matteo; A Pellegrino; L Dezzani; F-X Mahon; M Baccarani; F J Giles
Journal:  Leukemia       Date:  2015-10-06       Impact factor: 11.528

9.  Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Authors:  M Ilander; U Olsson-Strömberg; H Schlums; J Guilhot; O Brück; H Lähteenmäki; T Kasanen; P Koskenvesa; S Söderlund; M Höglund; B Markevärn; A Själander; K Lotfi; A Dreimane; A Lübking; E Holm; M Björeman; S Lehmann; L Stenke; L Ohm; T Gedde-Dahl; W Majeed; H Ehrencrona; S Koskela; S Saussele; F-X Mahon; K Porkka; H Hjorth-Hansen; Y T Bryceson; J Richter; S Mustjoki
Journal:  Leukemia       Date:  2016-11-28       Impact factor: 11.528

10.  KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy.

Authors:  David T Yeung; Carine Tang; Ljiljana Vidovic; Deborah L White; Susan Branford; Timothy P Hughes; Agnes S Yong
Journal:  Blood       Date:  2015-10-23       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.